Wegovy Trial Involving Israeli Centers Reports Two-Year BMI Benefit in Young Children
Children aged six to 11 with obesity who received semaglutide in the STEP Young trial had a lower body mass index after approximately two years, according to findings disclosed Monday. The study included 16 participants from Israel, with Schneider Children’s Medical Center, Shamir Medical Center and Rambam among its participating centers. At 104 weeks, the analysis accounting for participants who did not remain on treatment showed a 9.4% BMI reduction with semaglutide, compared with an 8.4% increase with placebo. At 68 weeks, the corresponding figures were a 13.5% reduction and a 2.7% increase, a statistically significant difference of 16.2 percentage points. These figures describe changes in BMI, rather than percentage body-weight loss. The randomized, double-blind trial combined weekly injections with a reduced-calorie diet and increased physical activity. The maximum weekly dose was 1.7 or 2.4 milligrams, depending on initial weight and tolerability. No unexpected safety concerns or safety signals involving growth or pubertal development were reported. Gastrointestinal effects associated with the treatment include nausea, vomiting, diarrhea, constipation and abdominal pain. Wegovy, whose active ingredient is semaglutide, remains unapproved in the United States for treating obesity in children younger than 12.

Commentary
Loading comments…